Bayesian Dosing Benefits.

Precision Dosing

“[Aminoglycoside Bayesian dose individualization] is a well-accepted practice… [Further studies] may not be feasible for ethical reasons.” – Ho et al.

The following published clinical literature demonstrates the benefits of precision dosing and Bayesian dose individualization.

Enhance Outcomes

1. Increased survival for childhood leukemia patients.
2. Improved survival for septic patients.
3. Increased patients in therapeutic range (chemotherapy).
4. Increased proportion of patients in the therapeutic range:
   • Warfarin
   • Enoxaparin
   • Vancomycin
   • Aminoglycosides
5. Decreased time to therapeutic stabilization.
6. Shortened febrile periods:
   • Gentamicin
   • Aminoglycosides

Reduce Adverse Events

Precision dosing reduces adverse events. The following RCTs demonstrate some of these benefits:

1. Reduced risk of toxic drug levels.
2. Reduction in bleeding events.
3. Reduction in bruising events.
4. Halve side-effects for chemotherapy patients.
5. Decreased discontinuation due to adverse events.
6. Decreased nephrotoxicity:
   • Gentamicin
   • Vancomycin

Reduce Costs

1. Cost-benefit ratio of between 4:1 and 52:1. (Review).
2. Save $2,500 (USD, 2012) per patient.
3. Substantial overall savings due to lowered mortality.
4. Reduce hospital stay length by more than 6 days per patient.
5. 4.6 day reduction in hospital stay length.